Aqueous core nanocapsules: A new solution for encapsulating doxorubicin hydrochloride

Drug Development and Industrial Pharmacy

Volumn 39, Issue 11, 2013, Pages 1706-1711

  Vrignaud, Sandy ^a,b   Anton, Nicolas ^c   Passirani, Catherine ^a   Benoit, Jean Pierre ^a,b,d   Saulnier, Patrick ^a  

^a UNIVERSITÉ D'ANGERS   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d PSL RESEARCH UNIVERSITY   (France)

Author keywords

Aqueous core; Doxorubicin hydrochloride; Nanocapsule; Nanoemulsion; Nanoparticle; Release

Indexed keywords

AQUEOUS CORE NANOCAPSULE; DOXORUBICIN; NANOCAPSULE; NANOCARRIER; UNCLASSIFIED DRUG;

ARTICLE; CARDIOTOXICITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG DIFFUSION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HYDROPHILICITY; IN VITRO STUDY; NANOENCAPSULATION; NONHUMAN; PHYSICAL CHEMISTRY; SUSTAINED DRUG RELEASE;

ANTIBIOTICS, ANTINEOPLASTIC; COMPLEMENT ACTIVATION; DELAYED-ACTION PREPARATIONS; DIFFUSION; DOXORUBICIN; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; MINERAL OIL; NANOCAPSULES; PARTICLE SIZE; PENTANES; PHARMACEUTICAL VEHICLES; PHYSICOCHEMICAL PHENOMENA; POLYETHYLENE GLYCOLS; SOLUBILITY; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS;

EID: 84885638765     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.730526     Document Type: Article

References (29)

1. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. (2002). Nanocapsule technology: A review. Crit Rev Ther Drug Carrier Syst, 19:99-134
2. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. (2000). Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm Res, 17:707-714
3. Hillaireau H, Le Doan T, Chacun H, Janin J, Couvreur P. (2007). Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers. Int J Pharm, 331:148-152
4. Anton N, Benoit JP, Saulnier P. (2008). Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release, 128:185-199
5. Anton N, Saulnier P, Gaillard C, Porcher E, Vrignaud S, Benoit JP.(2009). Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules. Langmuir, 25:11413-11419
6. Vrignaud S, Benoit JP, Saulnier P. (2011). Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles. Biomaterials, 32:8593-8604
7. Hillaireau H, Le Doan T, Besnard M, Chacun H, Janin J, Couvreur P. (2006). Encapsulation of antiviral nucleotide analogues azidothymidine- triphosphate and cidofovir in poly(isobutylcyanoacrylate) nanocapsules. Int J Pharm, 324:37-42
8. Paiphansiri U, Dausend J, Musyanovych A, Mailänder V, Landfester K. (2009). Fluorescent polyurethane nanocapsules prepared via inverse miniemulsion: Surface functionalization for use as biocarriers. Macromol Biosci, 9:575-584
9. Baier G, Musyanovych A, Dass M, Theisinger S, Landfester K.(2010). Cross-linked starch capsules containing dsDNA prepared in inverse miniemulsion as nanoreactors for polymerase chain reaction. Biomacromolecules, 11:960-968
10. Rosenbauer EM, Landfester K, Musyanovych A. (2009). Surfaceactive monomer as a stabilizer for polyurea nanocapsules synthesized via interfacial polyaddition in inverse miniemulsion. Langmuir, 25:12084-12091
11. Mdicaments antitumoraux et perspectives dans le traitement des cancers; vol. 6; chap. AFECT: Anthracyclines utilises en thrapeutique 2003, 364-411
12. Allen A. (1992). The cardiotoxicity of chemotherapeutic drugs. Semin Oncol, 19:529-542
13. Fundarò A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR.(2000). Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res, 42:337-343
14. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. (2001). Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release, 73:255-267
15. Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z et al. (2006). A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res, 23:1574-1585
16. Park JH, Cho YW, Son YJ, Kim K, Chung H, Jeong SY et al. (2006). Preparation and characterization of self-assembled nanoparticles based on glycol chitosan-bearing adriamycin. Colloid Polym Sci, 284:763-770
17. Rahman AM, Yusuf SW, Ewer MS. (2007). Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine, 2:567-583
18. Cho HJ, Yoon IS, Yoon HY, Koo H, Jin YJ, Ko SH et al. (2012). Polyethylene glycol-conjugated hyaluronic acid-ceramide selfassembled nanoparticles for targeted delivery of doxorubicin. Biomaterials, 33:1190-1200
19. Liu Y, Mi Y, Zhao J, Feng SS. (2011). Multifunctional silica nanoparticles for targeted delivery of hydrophobic imaging and therapeutic agents. Int J Pharm, 421:370-378
20. Vrignaud S, Anton N, Gayet P, Benoit JP, Saulnier P. (2011). Reverse micelle-loaded lipid nanocarriers: A novel drug delivery system for the sustained release of doxorubicin hydrochloride. Eur J Pharm Biopharm, 79:197-204
21. Jagielski N, Sharma S, Hombach V, Mailander V, Rasche V, Landfester K. (2007). Nanocapsules synthesized by miniemulsion technique for application as new contrast agent materials. Macromol Chem Phys, 208:2229-2241
22. Crespy D, Stark M, Hoffmann-Richter C, Ziener U, Landfester K. (2007). Polymeric nanoreactors for hydrophilic reagents synthesized by interfacial polycondensation on miniemulsion droplets. Macromolecules, 40:3122-3135
23. El-Gibaly I, Anwar M. (2004). Hemolysate-filled polyethyleneimine and polyurea microcapsules as potential red blood cell substitutes: Effect of aqueous monomer type on properties of the prepared microcapsules. Int J Pharm, 278:25-40
24. Soma CE, Dubernet C, Bentolila D, Benita S, Couvreur P.(2000). Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials, 21:1-7
25. Rahimi M, Wadajkar A, Subramanian K, Yousef M, Cui W, Hsieh JT et al. (2010). In vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled drug delivery. Nanomedicine, 6:672-680
26. Siepmann J, Peppas NA. (2001). Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev, 48:139-157
27. Missirlis D, Kawamura R, Tirelli N, Hubbell JA. (2006). Doxorubicin encapsulation and diffusional release from stable, polymeric, hydrogel nanoparticles. Eur J Pharm Sci, 29:120-129
28. Vonarbourg A, Passirani C, Saulnier P, Simard P, Leroux JC, Benoit JP. (2006). Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A, 78:620-628
29. Béduneau A, Saulnier P, Anton N, Hindré F, Passirani C, Rajerison H et al. (2006). Pegylated nanocapsules produced by an organic solvent-free method: Evaluation of their stealth properties. Pharm Res, 23:2190-2199